Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carisbamate adjunctive treatment for Lennox-Gastaut syndrome
2022-001256-42Phase 3Active
- Sponsor
- SK Life Science, Inc.
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Lennox-Gastaut syndrome (LGS) comparing Carisbamate adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoint: Percentage change from baseline in drop seizure frequency. Started Dec 2022; status: active.
02
Drugs
carisbamate
03
Conditions
Lennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on 2022-001256-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001256-42.